Results 81 to 90 of about 53,515 (238)

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.
Giuseppe Minniti   +9 more
doaj   +1 more source

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry.
Julien Bollard   +23 more
wiley   +1 more source

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

open access: yesESMO Open, 2020
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero   +12 more
doaj   +1 more source

Use of ipilimumab in the treatment of melanoma

open access: yes, 2013
Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been ...
Acharya UH, Jeter JM
core  

Ipilimumab: A Novel Treatment for Metastatic Melanoma

open access: yes, 2011
Objective: To review the mechanism of action, pharmacokinetics, efficacy, safety, drug interactions, dosing, and economic considerations of ipilimumab.
Morgan E Culver   +3 more
core   +1 more source

A Case of Ipilimumab Induced Hypophysitis [PDF]

open access: yes, 2015
Introduction Ipilimumab (Yervoy®) is a human monoclonal antibody that has been shown to significantly improve survival in cases of metastatic melanoma.1 Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein receptor on the surface of T ...
Ukrainski, MD, Melinda   +3 more
core   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto   +7 more
wiley   +1 more source

Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden   +9 more
wiley   +1 more source

Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu   +9 more
wiley   +1 more source

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA [PDF]

open access: yes, 2016
Metastatic melanoma remains a refractory disease. Great progress in therapy of metastatic melanoma patients has been made in the recent five years. Targeted immunotherapy – a selective effect on lymphocytes signal molecules - became a principally new ...
I. V. SAMOILENKO   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy